Compass’ psilocybin shows six-month durability in Phase III trial

Phase 3positivepsilocybin-based therapyPositive

AI Analysis

Summary

Compass Pathways' psilocybin-based therapy demonstrated six-month durability in Phase III trials, with the company having already submitted for FDA approval based on previous Phase III success.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Six-month durability demonstrated in Phase III trial

Importance:7/10

Sentiment:

0.70

psilocybinPhase IIIFDA approval pendingmental health

Related Companies

$CMPS

Read the original article

Published by Clinical Trials Arena on July 7, 2026 2:31 PM

Read Original